Tofaxen (Tofacitinib 5 mg) | Janus Kinase Inhibitor

Medically Reviewed by Dr. Salma Elreedy, Clinical Oncologist, Sphinx Cure Oncology Center

Last Updated: March 8, 2026

Classification: Prescription-Only Medicine (POM)

Prescription-Only Notice: This medication requires a valid prescription, baseline health screenings, and rigorous clinical monitoring due to significant side effect profiles.

The FDA approved Tofaxen (tofacitinib 5 mg) is an oral prescription medication classified as a Janus kinase (JAK) inhibitor. It contains similar active pharmaceutical ingredients to the innovator brand Xeljanz. While primarily indicated for the treatment of severe autoimmune and inflammatory conditions such as Rheumatoid Arthritis (RA) and Ulcerative Colitis (UC), it has an emerging supportive role in clinical oncology. Specialists occasionally utilize tofacitinib to manage severe, steroid-refractory immune-related adverse events (irAEs) induced by cancer immunotherapy.

Specialist Guidelines and Patient Query Response

What are the exact clinical indications for this medication?

Tofacitinib is prescribed for adults with moderately to severely active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Ulcerative Colitis who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blockers. In a specific oncology context, if a patient develops severe autoimmune toxicities (such as immunotherapy-induced colitis or arthritis) after receiving checkpoint inhibitors, an oncologist may prescribe this medication off-label to suppress the immune hyperactivation.

How does this medication work at a cellular level?

Tofacitinib operates within the JAK/STAT signaling pathway. When inflammatory cytokines bind to receptors on the surface of immune cells, they rely on Janus kinase (JAK) enzymes to transmit the signal into the cell nucleus via STAT proteins.

By inhibiting JAK1 and JAK3 enzymes, tofacitinib effectively blocks this intracellular communication. This prevents the DNA transcription of inflammatory proteins, rapidly reducing systemic immune hyperactivation and tissue inflammation.

What is the standard dosage and administration protocol?

• Standard Dose: For most rheumatological indications, the standard dosage is 5 mg taken orally twice daily.

• Administration: The tablets can be taken with or without food.

• Missed Doses: If a dose is missed, skip that dose and take the next tablet at the regularly scheduled time. Never take two doses simultaneously to make up for a missed tablet.

What are the major safety concerns and side effects?

Tofacitinib carries strict FDA Black Box Warnings. Because it fundamentally suppresses the immune system, it alters your cardiovascular and oncological risk profile.

• Malignancy Risk: Clinical data shows an increased risk of certain cancers (especially lymphoma and lung cancer) compared to TNF inhibitors.

  • Actionable Advice: Routine cancer screenings must be strictly maintained. It is generally avoided in patients with a recent history of active malignancy unless absolutely necessary.

• Cardiovascular Events: There is a higher risk of Major Adverse Cardiovascular Events (MACE), including heart attacks and stroke, particularly in patients over 50 with existing cardiac risk factors.

• Infections: Upper respiratory infections, urinary tract infections, and shingles (herpes zoster) are common.

  • Actionable Advice: Report any signs of infection, such as fever or chills, to your doctor immediately. Ensure routine vaccinations are up to date prior to initiating therapy.

What does the clinical trial data show?

The safety and efficacy of tofacitinib are grounded in extensive global trials:

• ORAL Surveillance Trial: Published in The New England Journal of Medicine, this critical post-marketing safety trial established the increased risk of major cardiovascular events and malignancies with tofacitinib compared to TNF inhibitors, forming the basis for current prescribing precautions.

• ORAL Solo Trial: This Phase 3 trial established its efficacy in RA, demonstrating that 59% of patients taking tofacitinib achieved significant symptom improvement (ACR20) at 3 months.

• OCTAVE Trials: These trials confirmed the drug’s efficacy in Ulcerative Colitis, showing significantly higher rates of mucosal healing and clinical remission compared to a placebo.

Precautions & Special Populations

• Hepatic & Renal Impairment: Patients with moderate hepatic impairment or moderate-to-severe renal impairment require strict dose adjustments (typically reduced to 5 mg once daily). It is contraindicated for patients with severe hepatic impairment.

• Pregnancy and Lactation: Tofacitinib exhibits embryo-fetal toxicity. Female patients of reproductive potential must use highly effective contraception during treatment and for at least 4 weeks following the final dose. Breastfeeding is strictly contraindicated.

• Storage Logistics: Store at standard room temperature (20°C to 25°C). Keep tablets in their original blister packaging to protect against moisture. Cold-chain logistics are not required.

Manufacturer Trust & Global Access

Manufacturer Quality Assurance: Tofaxen is manufactured in Bangladesh by Everest Pharmaceuticals. The production facility operates strictly under WHO-GMP (World Health Organization – Good Manufacturing Practices) guidelines. Comprehensive comparative dissolution and stability testing are conducted to ensure strict bioequivalence to the innovator product (Xeljanz), ensuring the active pharmaceutical ingredient performs identically in a clinical setting.

Global Distribution: For patients located in regions where generic tofacitinib is currently inaccessible, the medication can be procured via established global distribution frameworks. Patients with a valid specialist prescription can access the therapy under “Named Patient” or personal importation regulations, utilizing secure, temperature-logged supply chains to ensure the drug’s structural integrity upon delivery.

Patient FAQs

Can tofacitinib cure rheumatoid arthritis or ulcerative colitis?

No. There is currently no cure for these chronic autoimmune conditions. Tofacitinib is a disease-modifying therapy designed to manage symptoms, reduce inflammatory flare-ups, and prevent long-term joint or intestinal mucosal damage.

Can I take tofacitinib if I am currently receiving cancer treatment?

This must be decided by a multidisciplinary team. Because tofacitinib suppresses the immune system, it is generally contraindicated during active cancer therapy. However, if a patient develops severe, life-threatening autoimmune side effects from cancer immunotherapy, an oncologist may carefully utilize it to manage those specific complications.

Does this medication interact with other drugs?

Yes. Tofacitinib is metabolized in the liver by the CYP3A4 enzyme. Medications that inhibit this enzyme (such as ketoconazole or certain antibiotics) will increase the concentration of tofacitinib in your bloodstream, requiring a clinical dose reduction.

General Medical Disclaimer: The clinical information provided below is strictly for educational and informational purposes. It does not replace a formal consultation with your primary physician or oncologist. Tofaxen is a potent immunosuppressive therapy and must be administered under the direct supervision of a qualified medical professional.